Register for email alerts and news feeds:
This journal | BMJ Group
rss
Thorax 2007;62:657-660; doi:10.1136/thx.2007.084228
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society.

EDITORIAL

Biomarkers in COPD

Biomarkers in COPD: time for a deep breath

R A Stockley

Correspondence to:
Correspondence to:
Professor R A Stockley
Department of Medicine, University Hospital Birmingham, Edgbaston, Birmingham B15 2TH, UK; r.a.stockley@bham.ac.uk


Biomarkers need to fulfil several distinct requirements before they can be considered a valid indicator of chronic diseases such as COPD

The first 150 words of the full text of this article appear below.

Chronic obstructive pulmonary disease (COPD) has become recognised as a priority area for management of healthcare resources and development of new therapeutic strategies. This is based largely on economic burden and the excessive morbidity and mortality associated with the condition. The result has been a profusion of publications in recent years, many of which start with the observations that "COPD is currently the fifth and by the year 2020 will become the third or fourth leading cause of morbidity and mortality worldwide".

More recently, the COPD literature has entered a second phase. This has arisen from the appreciation that COPD is more than a respiratory inflammatory condition and is associated with manifestations outside the lung. This has led to the concept that COPD is a systemic disease and has resulted in a rapid increase in papers exploring this aspect. Initial studies were primarily based on the association . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Lomas, D A, Silverman, E K, Edwards, L D, Miller, B E, Coxson, H O, Tal-Singer, R, on behalf of the Evaluation of COPD Longitudinally, (2008). Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 63: 1058-1063 [Abstract] [Full Text]  
  • Luisetti, M., Ma, S., Iadarola, P., Stone, P. J., Viglio, S., Casado, B., Lin, Y. Y., Snider, G. L., Turino, G. M. (2008). Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 32: 1146-1157 [Abstract] [Full Text]  
  • Vestbo, J. (2008). COPD, diagrams and traditions: time to move on?. Thorax 63: 755-756 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Chest Medicine Jobs

Chest Medicine Jobs